Adagene Inc. (ADAG)

2.3300 +0.0800 (+3.56%) At close: 04:00PM EDT

Adagene Inc.

Building C14
4th Floor No. 218, Xinghu Street Suzhou Industrial Park
Suzhou 215123
China
86 512 8777 3632
https://www.adagene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 174

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peter P. Luo Ph.D.	Co- Founder, Chairman, CEO and President of R&D	N/A	N/A	1966
Mr. Man Kin Tam M.B.A.	CFO & Director	N/A	N/A	1977
Dr. Jc Xu M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	1965
Ms. Ami Celeste Knoefler	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Ling Zhou	Head of Human Resources	N/A	N/A	N/A
Dr. Qinghai Zhao	Chief Manufacturing Officer	N/A	N/A	1961
Ms. Yan Li M.B.A.	Senior VP of Bioinformatics & Information Technology and Director	N/A	N/A	1975
Ms. Xiaohong She	Senior VP & Head of Clinical Operations	N/A	N/A	1967
Dr. Guizhong Liu Ph.D.	Senior Vice President of Early Drug Discovery	N/A	N/A	1971
Mr. Alexander Goergen	VP & Head of Business Development	N/A	N/A	1987

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Corporate governance

Adagene Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.